- Home
- ATYR vs FLUX Comparison
ATYR vs FLUX Comparison
Compare ATYR & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- FLUX
- Stock Information
- Founded
- ATYR 2005
- FLUX N/A
- Country
- ATYR United States
- FLUX United States
- Employees
- ATYR N/A
- FLUX N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- FLUX Industrial Machinery/Components
- Sector
- ATYR Health Care
- FLUX Miscellaneous
- Exchange
- ATYR Nasdaq
- FLUX Nasdaq
- Market Cap
- ATYR 105.8M
- FLUX 98.5M
- IPO Year
- ATYR 2015
- FLUX N/A
- Fundamental
- Price
- ATYR $0.97
- FLUX $4.22
- Analyst Decision
- ATYR Buy
- FLUX Strong Buy
- Analyst Count
- ATYR 6
- FLUX 2
- Target Price
- ATYR $8.88
- FLUX $6.00
- AVG Volume (30 Days)
- ATYR 7.8M
- FLUX 796.7K
- Earning Date
- ATYR 11-11-2025
- FLUX 09-16-2025
- Dividend Yield
- ATYR N/A
- FLUX N/A
- EPS Growth
- ATYR N/A
- FLUX N/A
- EPS
- ATYR N/A
- FLUX N/A
- Revenue
- ATYR N/A
- FLUX $66,434,000.00
- Revenue This Year
- ATYR $420.85
- FLUX $8.23
- Revenue Next Year
- ATYR $1,513.40
- FLUX $24.72
- P/E Ratio
- ATYR N/A
- FLUX N/A
- Revenue Growth
- ATYR N/A
- FLUX 9.22
- 52 Week Low
- ATYR $0.68
- FLUX $1.15
- 52 Week High
- ATYR $7.29
- FLUX $7.55
- Technical
- Relative Strength Index (RSI)
- ATYR 32.08
- FLUX 44.17
- Support Level
- ATYR $0.94
- FLUX $5.06
- Resistance Level
- ATYR $1.02
- FLUX $7.55
- Average True Range (ATR)
- ATYR 0.08
- FLUX 1.00
- MACD
- ATYR 0.12
- FLUX -0.28
- Stochastic Oscillator
- ATYR 31.27
- FLUX 0.60
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.